ENTITY
Shijiazhuang Yiling Pharmaceutical

Shijiazhuang Yiling Pharmaceutical (002603 CH)

41
Analysis
Health CareChina
Shijiangzhuang Yiling Pharmaceutical Co Ltd develops, produces and sells Chinese patent medicine. The Company's major products include Tongxinluo capsules, Shensongyangxin capsules, Lotus Qingwen capsules, Qili Qiangxin capsules and Bazi Bushen capsules.
more
05 Nov 2024 05:30

CSI300 Index Rebalance Preview: Rising Markets and ETF Creations Take Round-Trip Trade to US$8.5bn

There could be 17 changes in Dec. Estimated 1-way turnover is 3%; 1-way trade is US$4.3bn. There are 14 stocks with over 2x ADV to trade. The adds...

Logo
220 Views
Share
05 May 2024 16:02

China Healthcare Weekly (May.5) - Overvaluation in Primary Market, RDC to Be Hot Spot, Yiling Pharma

Only foreign markets are able to “digest” high valuation of China's biotech assets in primary market. RDC/RLT will become the next hot area for...

Logo
398 Views
Share
11 Dec 2023 09:10

Shijiazhuang Yiling Pharmaceutical (002603.CH) - Valuation Rebound Is Worth Looking Forward To

Yiling’s performance faces a sharp decline without the pandemic catalyst, but the fundamentals are not that bad. Valuation is expected to bounce...

Logo
359 Views
Share
bearishHKEX
19 Nov 2023 05:30

Index Rebalance & ETF Flow Recap: FRTIB, Japan, CSI300, CSI500, STAR50, WuXi XDC, Asahi

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
650 Views
Share
16 Jun 2022 09:11

China Reopen - Opportunities and Challenges in China Healthcare

As China restores normal production/life, we analyzed positive/negative impact on different healthcare sectors. There could be policy shifts. What...

Logo
337 Views
Share
x